NCT03611153View on ClinicalTrials.gov

Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

February 11, 2022

Study Completion Date

February 24, 2022

Conditions
Heart Failure
Interventions
DRUG

AZD4831 Oral Myeloperoxidase Inhibitor

A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.

DRUG

Placebo oral capsule

A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

Mayo Clinic

OTHER